AIM ImmunoTech Inc. (LON:0A4Y)

Market Cap	6.98M
Revenue (ttm)	141.76K
Net Income (ttm)	-17.85M
Shares Out	n/a
EPS (ttm)	-0.34
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600
Average Volume	9,702
Open	0.139
Previous Close	0.149
Day's Range	0.122 - 0.139
52-Week Range	0.146 - 0.478
Beta	-0.30
RSI	38.01
Earnings Date	Apr 2, 2025

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1966
• Employees: 28
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4Y

Financial Performance

In 2023, AIM ImmunoTech's revenue was $202,000, an increase of 43.26% compared to the previous year's $141,000. Losses were -$28.96 million, 48.9% more than in 2022.

Financial numbers in USD